On March 3, 2025 Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, reported that the results of its CLARITI study have been selected for a distinguished plenary presentation at the upcoming Digestive Disease Week (DDW) 2025 conference, taking place May 5, 2025 (Press release, Immunovia, MAR 3, 2025, View Source [SID1234650857]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The CLARITI study was selected as one of only six abstracts to be presented at the AGA Institute Council’s Pancreatic Disorders Section Distinguished Abstract Plenary—an honor reserved for research demonstrating exceptional scientific and clinical impact.
Dr. Aimee Lee Lucas, Chief of Gastroenterology and Hepatology at Mount Sinai West and Mount Sinai Morningside Hospitals and Professor of Medicine at Icahn School of Medicine, will present the CLARITI study findings at DDW 2025. Her presentation, titled "Clinical validation of a novel blood-based multi-biomarker test for the early detection of pancreatic ductal adenocarcinoma (PDAC) in an independent high-risk population shows similar high performance as observed in its model development study," highlights the study’s robust methodology and the strong performance of Immunovia’s next-generation test.
As a member of the Immunovia Scientific Advisory Board, Dr. Lucas was integral to the study’s design and played a key role in the collection of blood samples.
"I am excited to present these data at the world’s largest conference for gastroenterologists. Selection of these study results for a distinguished plenary oral presentation underscores the rigor of the CLARITI validation study and the strong performance of the Immunovia test in the study," says Dr. Aimee Lee Lucas.
"We are very proud to see the CLARITI study receive this remarkable recognition. It’s a strong statement about the quality of our science and it highlights the importance of the unmet clinical need our new test addresses," says Jeff Borcherding, Immunovia CEO.